Metrion Biosciences’ Business Development Executive Dr Anca Haralambie will be attending On Helix Digital 2021 which takes place on 5th and 6th July.
On Helix is the One Nucleus flagship conference, bringing together professionals within the One Nucleus network to present and discuss the main innovation and technology trends in healthcare research and development.
Throughout the one and a half days of ON Helix, speakers will address the latest innovations and technologies in Medicines Discovery in a Brave New World.
ON Helix 2021 offers:
- High content mix of plenary talks and panels from key opinion leaders
- Networking and 1 to 1 virtual meetings with delegates from across the international Life Science and Healthcare industry
- Innovation Workshops scheduled on the days surrounding ON Helix for further technical and business insight
To arrange a partnering meeting with Anca please email email@example.com
Metrion Biosciences is a UK-based Contract Research Organization (CRO) located within the Cambridge bio cluster, one of Europe’s largest bioscience research hubs. Our state of the art laboratories at Granta Park house high quality facilities for native and engineered cell line and induced pluripotent stem cell culture, a comprehensive suite of automated patch clamp platforms, multiple manual patch clamp rigs, fluorescence-based screening capability and laboratory data management and reporting systems. Our company is focused upon delivering a range of high quality ion channel drug discovery services. We provide highly skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays. We combine in depth target class knowledge and high quality screening assays with highly experienced and collaborative drug discovery managers to keep your research focused upon meeting both objectives and timelines. Our team has successfully delivered many projects on behalf of our clients from once off screening projects to fully integrated drug discovery programmes delivering clinical candidates.